Börge Seeger

Practice Areas

Artificial Intelligence | IP/IT | Life Sciences | Technology Transactions | Licensing & Technology Transfer | Data Protection

Career

Börge Seeger is a partner at NEUWERK and head of the firm's IP/IT practice. He advises national and international clients on artificial intelligence, intellectual property, licensing, data protection, and technology transactions, with a particular focus on life sciences, healthcare, and digital health.

His practice covers the full AI lifecycle – from IP structuring and training data strategy, to deployment of AI-enabled products, complex licensing and SaaS arrangements, and AI-specific due diligence in M&A transactions. He regularly advises biotech, pharma, and medtech companies, AI-native ventures, and institutional clients on AI governance, EU AI Act compliance, and data-driven business models.

A technology lawyer by training, Seeger has specialised in IT and digital law since the outset of his career. He is a lecturer at the Northern Institute of Technology (NIT) at TU Hamburg and co-founded neuwerk.ai, a practitioner-led AI training platform for legal professionals. He speaks regularly at conferences and industry events on AI and technology law, most recently at trade fairs for the life sciences industry.

Languages Spoken

German, English

Professional Memberships

Fellow, Center for Internet and Society, Stanford Law School | Certified Licensing Professional (CLP) | Certified AI Competence Expert (CAICE) | Lecturer, Northern Institute of Technology (NIT) at TU Hamburg | Deutsch-Amerikanische Juristenvereinigung (DAJV) | Deutsche Gesellschaft für Rechtsinformatik (DGRI) | Licensing Executives Society (LES) | Vereinigung für Gewerblichen Rechtsschutz und Urheberrecht (GRUR) | Rechtsanwaltskammer Hamburg

Publications

Germany chapter, Lexology In-Depth: Artificial Intelligence Law, Edition 2 (Lexology, ongoing contributor on AI law in Germany) | Joint Controller Agreement (Art. 26 DSGVO), in: Stief/Bromm (Hrsg.), Vertragshandbuch Pharma und Life Sciences, 2. Auflage, 2021 | How to divorce amicably – Zur Gestaltung der Beendigungsszenarien im Lizenzdeal, Going Public – Life Sciences, 18. Jahrgang, 2016 | Die Lizenz in der Insolvenz, Patentkommentar, transkript, 2016 | Der fliegende Gerichtsstand bei Internet-Sachverhalten, in: Leible/Sosnitza (Hrsg.), Onlinerecht 2.0: Alte Fragen – neue Antworten?, 2011 | Online Proxy Voting: A New Hope for Shareholder Democracy?, Thesis, Stanford Program in International Legal Studies (SPILS), Stanford Law School, 2004

Clients

Novartis | Evotec | Grünenthal | Polpharma Biologics | Sandoz | Secarna Pharmaceuticals | BioNTech | Fresenius | BP | Axel Springer | Unilever | Ströer | University of Cologne | DZIF | Navigo Proteins | Benfovir | MerLion Pharmaceuticals | biotx.ai | APOQLAR | MetaCompliance | ISBA Informatik Service | GoCAD | Oxolo | B&L Gruppe

Industry Sector Expertise

Life Sciences | Pharmaceuticals | Biotechnology | Digital Health | Healthcare | Medtech | Artificial Intelligence | Software & SaaS | Data & Privacy | Cybersecurity | Technology | Venture Capital / Start-ups

Personal

Börge has played the piano since the age of six. He is the father of three sons.

Expert in these Jurisdictions

Germany | European Union

Work Highlights

1. Polpharma Biologics / Sandoz: Represented Polpharma Biologics on multiple strategic out-licensing and manufacturing transactions underpinning a long-term global commercialization partnership with Sandoz, including a global exclusive license and supply agreement for its natalizumab biosimilar (Tyruko®), a first-to-market biosimilar to Tysabri, now commercially launched in the US and EU.

2. Novartis / GSK: Advised Novartis on its business swap with GSK comprising the sale of Novartis' vaccine business to GSK (USD 5.3bn), the acquisition of GSK's oncology business (USD 16bn), and the creation of a consumer health joint venture, including all carve-out related IP, manufacturing, and distribution matters.

3. Fresenius Digital Technology: Represented Fresenius Digital Technology on "Project SPLIT", one of the largest healthcare IT deals worldwide, involving the deconsolidation of Fresenius Medical Care and the large-scale outsourcing of central IT systems – including AI-enabled infrastructure – to Capgemini, covering approx. 1,000 sites in more than 80 countries.

4. Secarna Pharmaceuticals: Represented Secarna on a research and option agreement with Denali Therapeutics (Nasdaq: DNLI) for ASO therapies targeting neurodegenerative diseases, and on a research and licensing collaboration with Protalix BioTherapeutics (Nasdaq: PLX) for antibody-ASO combination therapies.

5. biotx.ai / HeartBeat.bio: Advised biotx.ai on a strategic License and Technology Access Agreement with HeartBeat.bio AG, granting exclusive access to biotx.ai's AI platform for identifying genetic targets in heart failure – an emerging model for AI-powered partnerships in precision drug discovery.

Education

Awards